Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 16;18:17448069221127180. doi: 10.1177/17448069221127180

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — (a) Effect of MT1 non selective antagonist Luzindole (Luz) and selective MT2 antagonist 4P-PDOT (4P) on Day activity in melatonin treated (2 week) animals: Both Luz and 4P have significantly blocked immobility and high activity effects of melatonin, while there was no difference in low activity effect. (b) Effect of MT1 non selective antagonist Luzindole (Luz) and selective MT2 antagonist 4P-PDOT (4P) on Night activity in melatonin treated (2 week) animals: Both Luz and 4P have significantly blocked immobility and low activity effects of melatonin, while high activity was only blocked by Luz significantly. From the night activity data, we have seen Luz has effectively blocked the effects of melatonin than 4P.